Why is nintedanib more expensive than pirfenidone?

Nintedanib (Nintedanib) and pirfenidone (Pirfenidone ) are anti-fibrotic drugs that are widely used to treat idiopathic pulmonary fibrosis (IPF), but the price of nintedanib is generally higher than that of pirfenidone. This price difference is mainly affected by many factors. First of all, from the perspective of drug development and structural complexity, nintedanib is a multi-target tyrosine kinase inhibitor. Its synthesis difficulty and molecular structure complexity are higher than those of pirfenidone, resulting in higher production costs, which is reflected in terminal pricing.

Secondly, nintedanib has a relatively wider range of indications, not only for the treatment of idiopathic pulmonary fibrosis, but also for systemic sclerosis-related interstitial lung disease (SSc-ILD) and certain progressive interstitial lung disease (ILD) subtypes. Because it covers more disease areas, pharmaceutical companies will formulate higher price strategies based on the clinical value and broad application potential of the drug when pricing, which is one of the reasons why its price is higher than pirfenidone.

Third, the patent protection period of nintedanib ends later than that of pirfenidone, and there are fewer substitute generic drugs on the market. In comparison, generic versions of pirfenidone are more common in domestic and foreign markets, leading to fierce price competition and thus lowering the overall price level. Because nintedanib is protected by patent, the original drug still dominates the market, and the price naturally remains high.

Finally, the coverage method of medical insurance policies also affects the prices of both. Although both have been included in the medical insurance catalog, the reimbursement ratios, qualifications and regional implementation policies are slightly different, causing some patients to feel that nintedanib has greater cost pressure in terms of actual payment. Therefore, from the perspective of the difficulty of research and development of the drug itself, breadth of indications, patent protection status and medical insurance coverage, the higher price of nintedanib than pirfenidone is the result of a combination of factors.

Reference materials:https://www.esbriet.com/